688180 君实生物
盘后交易 07-03 15:00:00
资讯
新帖
简况
北向资金7月2日净卖出君实生物-U15.12万股 连续3日减持
自选股智能写手 · 09:30
北向资金7月2日净卖出君实生物-U15.12万股 连续3日减持
君实生物(01877):6月累计回购3.44万股A股
智通财经 · 07-02 19:03
君实生物(01877):6月累计回购3.44万股A股
君实生物(688180.SH):已累计回购0.0828%股份
格隆汇资讯 · 07-02 18:02
君实生物(688180.SH):已累计回购0.0828%股份
南向资金6月28日净卖出君实生物51.76万股 连续3日减持
自选股智能写手 · 07-02 09:31
南向资金6月28日净卖出君实生物51.76万股 连续3日减持
7月1日君实生物现513万元大宗交易
证券之星 · 07-01 17:20
7月1日君实生物现513万元大宗交易
浦东创新药再获新进展!君实生物特瑞普利单抗三阴性乳腺癌适应症获批
浦东发布 · 06-27
浦东创新药再获新进展!君实生物特瑞普利单抗三阴性乳腺癌适应症获批
君实生物6月27日现1笔大宗交易 成交金额590万元
智能小浪 · 06-27
君实生物6月27日现1笔大宗交易 成交金额590万元
6月27日君实生物现590万元大宗交易
证券之星 · 06-27
6月27日君实生物现590万元大宗交易
君实生物(01877)上涨5.23%,报11.66元/股
金融界 · 06-26
君实生物(01877)上涨5.23%,报11.66元/股
君实生物盘中异动 早盘股价大涨5.23%报11.661港元
自选股智能写手 · 06-26
君实生物盘中异动 早盘股价大涨5.23%报11.661港元
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
有连云 · 06-26
高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。
港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
智通财经 · 06-26
港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批
君实生物获融资买入0.31亿元,近三日累计买入0.46亿元
金融界 · 06-26
君实生物获融资买入0.31亿元,近三日累计买入0.46亿元
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批
阿斯达克财经 · 06-26
君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批
君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准
智通财经 · 06-25
君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准
君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批
智通财经 · 06-25
君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批
君实生物:特瑞普利单抗新适应症上市申请获批
证券时报 · 06-25
君实生物:特瑞普利单抗新适应症上市申请获批
君实生物:霍依莲女士当选为公司第四届监事会职工代表监事
金融界 · 06-21
君实生物:霍依莲女士当选为公司第四届监事会职工代表监事
君实生物(01877):熊俊获选为第四届董事会主席
智通财经 · 06-21
君实生物(01877):熊俊获选为第四届董事会主席
君实生物(01877)选举熊俊为第四届董事会董事长
智通财经网 · 06-21
君实生物(01877)选举熊俊为第四届董事会董事长
加载更多
公司概况
公司名称:
上海君实生物医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-15
主营业务:
上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权(EUA)的国产COVID-19治疗药物埃特司韦单抗。
发行价格:
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":28.9,"timestamp":1719990000000,"preClose":28.71,"halted":0,"volume":2660384,"delay":0,"floatShares":765000000,"shares":986000000,"eps":-2.0524,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.19,"latestTime":"07-03 15:00:00","open":28.71,"high":29.35,"low":28.62,"amount":77390200,"amplitude":0.0254,"askPrice":28.9,"askSize":175,"bidPrice":28.88,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-2.0524,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"adjPreClose":28.71,"symbolType":"stock_kcb","openAndCloseTimeList":[[1719970200000,1719977400000],[1719982800000,1719990000000]],"highLimit":31.58,"lowLimit":25.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":985689871,"pbRate":4.15,"roa":"--","roe":"--","epsLYR":-2.32,"committee":-0.383686,"marketValue":28486000000,"floatMarketCap":22095000000,"peRate":-14.081075,"changeRate":0.0066,"turnoverRate":0.0035,"status":0,"afterMarket":{"amount":0,"volume":0,"close":28.9,"buyVolume":0,"sellVolume":0,"time":1719991771963,"indexStatus":"盘后交易 07-03 15:29:31","preClose":28.71}},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2448117268","title":"北向资金7月2日净卖出君实生物-U15.12万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448117268","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448117268?lang=zh_cn&edition=full","pubTime":"2024-07-03 09:30","pubTimestamp":1719970239,"startTime":"0","endTime":"0","summary":"7月2日,北向资金减持君实生物-U15.12万股连续3日减持。截止当日收盘,沪股通共持有君实生物-U976.75万股,占流通股1.27%。沪股通减持金额前五个股分别为工业富联、万华化学、紫金矿业、洛阳钼业、恒瑞医药。君实生物-U近5个交易日上涨0.84%,沪股通累计减持78.87万股;近20个交易日上涨2.21%,沪股通累计减持532.02万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407030934199ef86c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407030934199ef86c56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK0239","01877"],"gpt_icon":0},{"id":"2448134008","title":"君实生物(01877):6月累计回购3.44万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448134008","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448134008?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:03","pubTimestamp":1719918181,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,2024年6月,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份3.44万股,占公司总股本比例为0.0035%,回购成交的最高价为人民币29.14元/股,最低价为人民币29.03元/股,支付的资金总额为人民币99.998万元。本次回购股份进展符合法律法规的规定及公司回购股份方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","399300","BK1583","BK1161","BK1515","688180","159982","BK0239"],"gpt_icon":0},{"id":"2448136958","title":"君实生物(688180.SH):已累计回购0.0828%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448136958","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448136958?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:02","pubTimestamp":1719914562,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨君实生物(688180.SH)公布,截至2024年6月30日,公司通过上海证券交易所交易系统以集中竞价交易方式已累计回购股份815,871股,占公司总股本比例为0.0828%,回购成交的最高价为人民币41.69元/股,最低价为人民币29.03元/股,支付的资金总额为人民币30,883,207.73元(不含印花税、交易佣金等交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021802489ef3b07d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021802489ef3b07d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2448297602","title":"南向资金6月28日净卖出君实生物51.76万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2448297602","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448297602?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:31","pubTimestamp":1719883893,"startTime":"0","endTime":"0","summary":"6月28日,南向资金减持君实生物51.76万股连续3日减持。截止当日收盘,港股通共持有君实生物9148.36万股,占流通股41.70%。君实生物近5个交易日上涨3.72%,港股通累计减持26.22万股;近20个交易日上涨1.92%,港股通累计增持137.96万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941169ef0d58f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020941169ef0d58f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","01877","BK0239"],"gpt_icon":0},{"id":"2448961142","title":"7月1日君实生物现513万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2448961142","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448961142?lang=zh_cn&edition=full","pubTime":"2024-07-01 17:20","pubTimestamp":1719825631,"startTime":"0","endTime":"0","summary":"近三个月该股共发生2笔大宗交易,合计成交3800.0手,折价成交1笔,溢价成交1笔。该股在过去半年内已有共计171.15万股限售解禁股上市,占公司总股本的0.17%。截至2024年7月1日收盘,君实生物报收于28.61元,下跌1.51%,换手率0.46%,成交量3.5万手,成交额9916.5万元。该股最近90天内共有8家机构给出评级,买入评级8家;过去90天内机构目标均价为56.15。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100022668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","BK1583","BK1515","01877","688180"],"gpt_icon":0},{"id":"2446358054","title":"浦东创新药再获新进展!君实生物特瑞普利单抗三阴性乳腺癌适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446358054","media":"浦东发布","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446358054?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:40","pubTimestamp":1719484813,"startTime":"0","endTime":"0","summary":"近日,浦东创新药企业——君实生物宣布,由公司自主研发的抗PD-1单抗药物特瑞普利单抗注射液(拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗新适应症上市申请于近日获得国家药品监督管理局批准。这是特瑞普利单抗在中国内地获批的第十项适应症。据统计,全球乳腺癌的年新发病例数达231万,死亡病例数达67万,是全球女性发病率最高的癌症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271846119f6ba320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271846119f6ba320&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688180"],"gpt_icon":0},{"id":"2446049589","title":"君实生物6月27日现1笔大宗交易 成交金额590万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446049589","media":"智能小浪","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446049589?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:40","pubTimestamp":1719481200,"startTime":"0","endTime":"0","summary":" 6月27日,君实生物收涨0.07%,收盘价为29.21元,发生1笔大宗交易,合计成交量20万股,成交金额590万元。 进一步统计,近3个月内该股累计发生1笔大宗交易,合计成交金额为590万元。该股近5个交易日累计上涨1.85%,主力资金合计净流入100.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-06-27/doc-incaemyf5311050.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-06-27/doc-incaemyf5311050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","688180","BK0239","01877","BK1583","BK1161"],"gpt_icon":0},{"id":"2446586225","title":"6月27日君实生物现590万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2446586225","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446586225?lang=zh_cn&edition=full","pubTime":"2024-06-27 17:20","pubTimestamp":1719480029,"startTime":"0","endTime":"0","summary":"近三个月该股共发生1笔大宗交易,合计成交2000.0手,溢价成交1笔。该股在过去半年内已有共计2.61亿股限售解禁股上市,占公司总股本的26.45%。截至2024年6月27日收盘,君实生物报收于29.21元,上涨0.07%,换手率0.67%,成交量5.15万手,成交额1.51亿元。该股最近90天内共有8家机构给出评级,买入评级8家;过去90天内机构目标均价为56.15。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700033418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1583","BK1161","688180","BK0239","01877"],"gpt_icon":0},{"id":"2446846343","title":"君实生物(01877)上涨5.23%,报11.66元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446846343","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446846343?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:24","pubTimestamp":1719372254,"startTime":"0","endTime":"0","summary":"6月26日,君实生物(01877)盘中上涨5.23%,截至11:24,报11.66元/股,成交623.15万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法,特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年一季报,君实生物营业总收入3.81亿元、净利润-2.83亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26112441197821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01877","688180","BK1583","BK1161","BK1515","BK0239"],"gpt_icon":0},{"id":"2446757384","title":"君实生物盘中异动 早盘股价大涨5.23%报11.661港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446757384","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446757384?lang=zh_cn&edition=full","pubTime":"2024-06-26 11:24","pubTimestamp":1719372249,"startTime":"0","endTime":"0","summary":"2024年06月26日早盘11时24分,君实生物股票出现异动,股价快速拉升5.23%。截至发稿,该股报11.661港元/股,成交量50.44万股,换手率0.23%,振幅5.05%。资金方面,该股资金流入316.648万港元,流出164.413万港元。君实生物股票所在的生物技术行业中,整体跌幅为0.63%。截至本公告日期,特瑞普利单抗的10项适应症已于中国内地获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626112410af8f3828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626112410af8f3828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","01877","688180"],"gpt_icon":0},{"id":"2446438694","title":"高质量创新成为国产药品开发主旋律,港股创新药ETF(159567)跟踪指数走势占优,中国生物制药、君实生物、来凯医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446438694","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446438694?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:41","pubTimestamp":1719369706,"startTime":"0","endTime":"0","summary":"2024年6月26日,港股创新药板块领跑港股市场。盘面上,中国生物制药领涨,君实生物、来凯医药-B跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额高达5977万元。国联证券表示,高质量创新成为国产药品开发主旋律。进入2024年,创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","01877","688180","BK1161","BK1589","BK1521","BK1583","02105","BK1515"],"gpt_icon":0},{"id":"2446381270","title":"港股异动 | 君实生物(01877)涨超3% 特瑞普利单抗三阴性乳腺癌适应症在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446381270","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446381270?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:39","pubTimestamp":1719369574,"startTime":"0","endTime":"0","summary":"消息面上,君实生物宣布,由公司自主研发的抗PD-1单抗药物特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得国家药监局批准。这是特瑞普利单抗在内地获批的第十项适应症。天风证券此前指出,公司营业收入增长主要来自商业化药品销售收入的增长,其中核心产品特瑞普利单抗贡献突出。2023 年,特瑞普利单抗销售收入9.19 亿元,同比增长约24.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","BK1583","BK1515","01877","688180","YANG","07226","HSCEI","HSTECH"],"gpt_icon":0},{"id":"2446804395","title":"君实生物获融资买入0.31亿元,近三日累计买入0.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446804395","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446804395?lang=zh_cn&edition=full","pubTime":"2024-06-26 08:21","pubTimestamp":1719361305,"startTime":"0","endTime":"0","summary":"6月25日,沪深两融数据显示,君实生物获融资买入额0.31亿元,居两市第166位,当日融资偿还额0.12亿元,净买入1907.66万元。最近三个交易日,21日-25日,君实生物分别获融资买入0.09亿元、0.07亿元、0.31亿元。融券方面,当日融券卖出2.24万股,净买入15.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260821579f6599c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406260821579f6599c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1161","BK1515","688180"],"gpt_icon":0},{"id":"2446822291","title":"君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446822291","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446822291?lang=zh_cn&edition=full","pubTime":"2024-06-26 01:48","pubTimestamp":1719337680,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布,收到国家药品监督管理局核准签发的《药品注册证书》,公司产品特瑞普利单抗(商品名:拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359097/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK0239","BK1583","BK1515","01877","688180"],"gpt_icon":0},{"id":"2446843481","title":"君实生物(01877):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2446843481","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446843481?lang=zh_cn&edition=full","pubTime":"2024-06-25 20:54","pubTimestamp":1719320064,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,公司收到国家药品监督管理局核准签发的《药品注册证书》,公司产品特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1 阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。截至本公告日期,特瑞普利单抗的10项适应症已于中国内地获批。在国际化布局方面,2023年10月,特瑞普利单抗已作为首款鼻咽癌药物在美国获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","688180","BK1583","BK1161","BK1515","BK0239"],"gpt_icon":0},{"id":"2446817835","title":"君实生物(688180.SH):特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446817835","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446817835?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:56","pubTimestamp":1719316611,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公告,近日,公司收到国家药品监督管理局核准签发的《药品注册证书》,特瑞普利单抗联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准,这是特瑞普利单抗在中国内地获批的第十项适应症。中国目前的晚期三阴性乳腺癌治疗仍以化疗为主,但无论单药或是联合化疗均疗效欠佳,中位生存期约为9至12个月,5年生存率不足30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","01877","BK1515","688180","BK1583"],"gpt_icon":0},{"id":"2446481970","title":"君实生物:特瑞普利单抗新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446481970","media":"证券时报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446481970?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:10","pubTimestamp":1719313805,"startTime":"0","endTime":"0","summary":"证券时报e公司讯,君实生物(688180)6月25日晚间公告,特瑞普利单抗(商品名:拓益®,产品代号:JS001)联合注射用紫杉醇(白蛋白结合型)用于经充分验证的检测评估PD-L1阳性(CPS≥1)的复发或转移性三阴性乳腺癌(TNBC)的一线治疗的新适应症上市申请获得批准,这是特瑞普利单抗在中国内地获批的第十项适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062519100995d6495d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062519100995d6495d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK0239"],"gpt_icon":0},{"id":"2445309764","title":"君实生物:霍依莲女士当选为公司第四届监事会职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2445309764","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445309764?lang=zh_cn&edition=full","pubTime":"2024-06-21 23:31","pubTimestamp":1718983889,"startTime":"0","endTime":"0","summary":"6月21日消息, 君实生物 公告称,第三届监事会任期届满,根据相关规定,公司于 2024 年 6 月 20 日召开职工代表大会,选举霍依莲女士为公司第四届监事会职工代表监事,任期与公司第四届监事会任期一致。霍依莲女士将与公司股东大会选举产生的 2 名非职工代表监事共同组成公司第四届监事会。截至本公告披露日,霍依莲女士未直接持有公司股份,并且在公司法等相关法律、法规和规定要求的任职条件上都符合要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406212339419f56ff5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406212339419f56ff5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1583","BK1515","688180","BK1161"],"gpt_icon":0},{"id":"2445765446","title":"君实生物(01877):熊俊获选为第四届董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2445765446","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445765446?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:28","pubTimestamp":1718980085,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,全部建议董事已于股东周年大会上获选,并构成第四届董事会。于2024年6月21日举行的第四届董事会第一次会议上,熊俊及李宁分别获选为第四届董事会主席及副主席,任期为三年,自董事会会议日期起生效,直至第四届董事会结束。于2024年6月20日举行的公司职工代表会议上,职工代表决议委任霍依莲为第四届监事会的职工代表监事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688180","BK1583","BK1515","01877","BK1161"],"gpt_icon":0},{"id":"2445757291","title":"君实生物(01877)选举熊俊为第四届董事会董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2445757291","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445757291?lang=zh_cn&edition=full","pubTime":"2024-06-21 21:27","pubTimestamp":1718976473,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 发布公告,公司董事会选举熊俊为公司第四届董事会董事长、NING LI(李宁)为公司第四届董事会副董事长,任期自公司董事会审议通过之日起至公司第四届董事会任期届满之日止。公司董事会同意聘任邹建军为公司总经理、首席执行官,聘任李聪为公司联席首席执行官,聘任张卓兵、SHENG YAO(姚盛)、GANG WANG(王刚)为公司副总经理,聘任许宝红为公司财务总监,聘任王征宇为公司董事会秘书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK1515","688180","BK1161","01877","BK1583"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区海趣路36、58号2号楼10层1003室","stockEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.0693},{"period":"3month","weight":0.0717},{"period":"6month","weight":-0.3037},{"period":"1year","weight":-0.2631},{"period":"ytd","weight":-0.3137}],"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","perCapita":"23654股","boardName":"医药制造业","registeredCapital":"98568万元","compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0291},{"period":"3month","weight":-0.0236},{"period":"6month","weight":0.0144},{"period":"1year","weight":-0.0761},{"period":"ytd","weight":0.0074}],"survey":" 上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权(EUA)的国产COVID-19治疗药物埃特司韦单抗。","serverTime":1719991774657,"listedPrice":55.5,"stockholders":"32322人(较上一季度减少2.07%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}